Last updated: February 19, 2026
This analysis examines Canadian patent CA2879982, focusing on its claims, scope, and surrounding patent landscape. The patent, titled "METHOD FOR TREATING CARDIOVASCULAR DISEASE," was filed on January 28, 2015, and granted on March 26, 2019. It relates to a specific method of treating cardiovascular disease using certain pharmaceutical compounds.
What is the Primary Subject Matter of CA2879982?
The core of patent CA2879982 concerns a method of treating cardiovascular disease. Specifically, the claims define a process involving the administration of particular chemical entities to a subject in need of such treatment. The patent focuses on the therapeutic application rather than the composition of matter itself, though the therapeutic agent is central to the claimed method.
The patent describes a method for treating cardiovascular disease. This method involves administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof to a subject. Formula I is defined within the patent as a specific chemical structure, detailed in the patent document. The method is indicated for conditions such as heart failure, myocardial infarction, and stroke.
What are the Key Claims Within CA2879982?
The patent's claims delineate the legal protection afforded to the invention. They are crucial for understanding the patent's scope and potential infringement.
Claim 1 is the independent claim and defines the broadest scope of the invention:
- A method for treating cardiovascular disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof:
(Formula I is detailed within the patent document and specifies a particular chemical structure and its substituents).
Dependent claims further refine the scope by adding specific parameters or limitations. Examples of such limitations, as typically found in pharmaceutical method-of-treatment patents, would include:
- The specific type of cardiovascular disease being treated (e.g., congestive heart failure, ischemic heart disease).
- The specific compound or salt of Formula I being administered.
- The dosage regimen or frequency of administration.
- The route of administration (e.g., oral, intravenous).
- The patient population or specific characteristics of the subject.
For a precise understanding of all dependent claims and their specific limitations, direct consultation of the patent document is necessary. However, the fundamental protection lies in the method of using a compound of Formula I for cardiovascular disease treatment.
What is the Technological and Therapeutic Scope of the Patent?
The technological scope of CA2879982 is centered on pharmaceutical interventions for cardiovascular ailments. The therapeutic scope targets a range of conditions recognized as significant public health challenges.
The patent's therapeutic scope encompasses the treatment of various cardiovascular diseases. These are conditions affecting the heart and blood vessels. The patent explicitly mentions or implies treatment for:
- Heart Failure: This includes systolic and diastolic heart failure, where the heart cannot pump blood effectively.
- Myocardial Infarction (Heart Attack): The patent's method can be used in the management or recovery phase following a heart attack.
- Stroke: Cardiovascular issues are a major risk factor for stroke, and the patent's method may address related pathological processes.
The technological scope involves the application of medicinal chemistry and pharmacology. The compound of Formula I is designed to interact with specific biological targets or pathways implicated in cardiovascular dysfunction. This could include modulation of:
- Cardiac contractility
- Vascular tone
- Inflammatory pathways
- Renal function relevant to cardiovascular health
The patent does not claim the compound itself, but rather its use in a specific therapeutic context. This focus on method-of-treatment claims has implications for patent enforcement and generic competition.
What is the Patent Landscape Surrounding CA2879982?
The patent landscape for CA2879982 reveals existing intellectual property that could impact its commercialization or create potential conflicts. This includes patents claiming the compound itself, other methods of treatment using related compounds, or formulations.
The patent landscape analysis involves identifying other patents and patent applications that may:
- Claim the Compound of Formula I: Patents claiming the compound of Formula I as a composition of matter would generally have a broader scope than method-of-treatment patents. If such a patent exists and is in force, it could block the manufacture and sale of the compound, even for uses claimed in CA2879982.
- Claim Different Methods of Treatment: Other patents might claim the use of the same compound for different therapeutic indications or using different administration routes or dosages that are distinct from those claimed in CA2879982.
- Claim Formulations or Delivery Systems: Patents might cover specific pharmaceutical compositions or devices designed to deliver the compound of Formula I.
- Claim Related Compounds: Patents covering structurally similar compounds that might also have cardiovascular benefits could create a crowded field and necessitate freedom-to-operate assessments.
Key Players in the Cardiovascular Drug Patent Landscape:
The field of cardiovascular therapeutics is highly competitive, with numerous pharmaceutical companies actively pursuing patent protection. Major entities involved in cardiovascular drug development and patenting include:
- Pfizer Inc.
- Merck & Co.
- Bristol-Myers Squibb Company
- Novartis AG
- AstraZeneca PLC
- Bayer AG
A comprehensive landscape analysis requires diligent searching of patent databases (e.g., Espacenet, USPTO, WIPO) using keywords, assignee names, and classification codes relevant to cardiovascular diseases and the specific chemical class of compounds related to Formula I. This search would identify granted patents and pending applications that could pose a challenge or offer collaborative opportunities.
What is the Exclusivity Period and Key Dates for CA2879982?
Understanding the exclusivity period is critical for R&D and investment planning, as it dictates when generic alternatives can enter the market.
- Filing Date: January 28, 2015
- Grant Date: March 26, 2019
- Term of Patent: In Canada, the term of a patent is 20 years from the filing date, subject to the payment of renewal fees.
Therefore, CA2879982 has a nominal expiration date of January 28, 2035.
Important Considerations for Exclusivity:
- Renewal Fees: Failure to pay annual renewal fees will result in the patent lapsing prematurely. This is a critical administrative aspect of maintaining patent rights.
- Regulatory Exclusivities: Beyond patent protection, pharmaceutical products may benefit from regulatory exclusivities granted by Health Canada, such as data protection or market exclusivity for new chemical entities. These are separate from patent terms.
- Patent Linkage: In Canada, the Patented Medicines (Notice of Compliance) Regulations provide a mechanism to address patent issues when an Abbreviated New Drug Submission (ANDS) is filed by a generic competitor. This "patent linkage" can extend de facto market exclusivity if patent validity or infringement is litigated.
The effective market exclusivity for a drug developed based on this patent will depend on the compound of Formula I being recognized as a "new chemical entity" by Health Canada, the presence of any linked patents, and successful navigation of the Patented Medicines (Notice of Compliance) Regulations.
What are the Potential Commercial and R&D Implications?
The analysis of CA2879982 provides several implications for commercial strategy and research and development decisions.
Commercial Implications:
- Market Entry Timing: The patent's expiry date of January 28, 2035, sets a benchmark for potential generic entry. However, regulatory exclusivities and patent linkage proceedings can alter this timeline.
- Licensing Opportunities: Companies holding this patent may seek licensing agreements with other pharmaceutical firms for co-development, manufacturing, or marketing rights. Conversely, companies seeking to develop treatments in this area may need to license the technology from the patent holder.
- Freedom to Operate: Competitors must conduct thorough freedom-to-operate analyses to ensure their own products or methods do not infringe upon the claims of CA2879982. This is particularly relevant for any drug targeting cardiovascular disease utilizing compounds similar in structure or mechanism to Formula I.
- Infringement Risk: For any entity developing or marketing a drug that employs the method claimed in CA2879982, there is a risk of patent infringement litigation. This risk is heightened if the compound used falls squarely within the definition of Formula I and is administered for the treatment of the claimed cardiovascular diseases.
R&D Implications:
- Pipeline Diversification: Companies may choose to develop next-generation therapies or combination therapies that circumvent or complement the patented method. This could involve developing compounds outside of Formula I or new therapeutic approaches for cardiovascular disease.
- Research Focus: The patent suggests that compounds related to Formula I have demonstrated efficacy in treating cardiovascular conditions. This could guide R&D efforts towards exploring:
- Optimizing the compound of Formula I (e.g., improving pharmacokinetics, reducing side effects).
- Identifying new therapeutic indications for the compound.
- Investigating the precise mechanism of action to discover new drug targets.
- Formulation Development: R&D can focus on novel drug delivery systems or formulations that enhance the therapeutic profile of the compound of Formula I, potentially leading to new patentable inventions.
Strategic Considerations:
The value of CA2879982 is intrinsically linked to the clinical and commercial success of the drug product that embodies the claimed method. If a specific compound of Formula I proves highly effective and safe, and addresses an unmet medical need in cardiovascular disease, the patent will hold significant value. Conversely, if the compound faces clinical challenges or market acceptance issues, the patent's commercial relevance diminishes, though its defensive value in blocking competitors remains.
Key Takeaways
- Canadian patent CA2879982 protects a method for treating cardiovascular disease through the administration of a compound of Formula I or its pharmaceutically acceptable salt.
- The patent's claims are focused on the therapeutic application, not the composition of matter itself.
- The nominal expiry date for CA2879982 is January 28, 2035, but this can be influenced by renewal fees and regulatory exclusivities.
- The surrounding patent landscape is critical, requiring analysis of patents covering the compound itself, related compounds, and different therapeutic methods.
- Commercial and R&D strategies must consider potential licensing opportunities, freedom-to-operate issues, infringement risks, and opportunities for innovation that build upon or circumvent the patented method.
Frequently Asked Questions
- Does CA2879982 prevent the sale of the compound of Formula I for any use?
No, CA2879982 claims specifically a method for treating cardiovascular disease. It does not claim the compound of Formula I itself, nor does it inherently prevent its sale for research purposes or for other, distinct therapeutic uses not covered by the patent's claims.
- What is the significance of "Formula I" in the patent claims?
"Formula I" represents a specific chemical structure or a defined genus of chemical structures described in detail within the patent document. The patent grants protection for the method of using compounds falling within this definition.
- How does the Canadian patent linkage system affect CA2879982?
If a generic drug manufacturer files an Abbreviated New Drug Submission (ANDS) for a drug that utilizes the method claimed in CA2879982, the patent holder can use the Patented Medicines (Notice of Compliance) Regulations to seek a stay of approval. This linkage process can effectively extend market exclusivity by litigating patent validity or infringement.
- Can a company develop a new formulation of the compound of Formula I and obtain separate patent protection?
Yes, novel formulations, delivery systems, or methods of administration for the compound of Formula I that offer new advantages (e.g., improved efficacy, reduced side effects, enhanced convenience) can potentially be the subject of new patent applications and granted patents.
- What are the implications if the compound of Formula I is already off-patent as a composition of matter?
If the compound of Formula I is no longer protected by a composition-of-matter patent (i.e., that patent has expired or never existed), CA2879982's method-of-treatment claim can still provide significant market exclusivity for the specific therapeutic use described. Generic manufacturers would need to avoid infringing this method claim, even if they can legally manufacture the compound.
Cited Sources
[1] Patent CA2879982. (2019, March 26). METHOD FOR TREATING CARDIOVASCULAR DISEASE. Canadian Intellectual Property Office.
